PROTEASE COMPOSITIONS FOR THE TREATMENT OF DAMAGED TISSUE

1 . A method for promoting the repair of a damaged tissue, comprising:

modulating the activity of a first protein selected from the group consisting of MMPs and TNFα; and

modulating the activity of a second protein selected from the group consisting of TIMPs and PDGF, wherein the first protein and the second protein are present at the site of the damaged tissue.

2 . The method of claim 1 , wherein the first and the second proteins are inflammation-related proteins.

3 . The method of claim 1 , wherein the modulation of the activity of the first protein comprises degradation of the first protein.

4 . The method of claim 1 , wherein the modulation of the activity of the second protein comprises protecting the second protein from degradation.

5 . The method of claim 1 , wherein the modulation of the first protein and the modulation of the second protein is mediated by administering a protease composition.

6 . The method of claim 5 , wherein the protease composition comprises:

at least one protease; and

a pharmaceutically acceptable carrier.

7 . The method of claim 6 , wherein the at least one protease is selected from one or more of aminopeptidase, aspartic endopeptidase, cysteine endopeptidase, cysteine-type carboxypeptidase, dipeptidase, dipeptidyl-peptidase, metallocarboxypeptidase, metalloendopeptidase, omega peptidase, peptidyl-dipeptidase, serine endopeptidase, serine-type carboxypeptidase, tripeptidyl-peptidase, threonine endopeptidase and variants, homologues, derivatives or fragments thereof.

8 . The method of claim 1 , wherein the damaged tissue is a wound.

9 . The method of claim 8 , wherein the wound is an acute wound or a chronic wound.

10 . The method of claim 1 , wherein the damaged tissue is an ulcer.

11 . The method of claim 1 , wherein the damaged tissue is the result of a cancer.

12 . A method of treating an inflammatory disease in a subject in need thereof comprising:

administering to the subject a therapeutically effective amount of a protease composition, wherein the composition is effective in modulating the activity of a first protein selected from the group consisting of MMPs and TNFα; and modulating the activity of a second protein selected from the group consisting of TIMPs and PDGF, wherein the first protein and the second protein are inflammation-related proteins.

13 . The method of claim 12 , wherein the modulation of the activity of the first protein comprises degradation of the first protein.

14 . The method of claim 12 , wherein the modulation of the activity of the second protein comprises protecting the second protein from degradation.

15 . The method of claim 12 , wherein the protease composition comprises:

at least one protease; and

a pharmaceutically acceptable carrier.

16 . The method of claim 15 , wherein the at least one protease is selected from one or more of aminopeptidase, aspartic endopeptidase, cysteine endopeptidase, cysteine-type carboxypeptidase, dipeptidase, dipeptidyl-peptidase, metallocarboxypeptidase, metalloendopeptidase, omega peptidase, peptidyl-dipeptidase, serine endopeptidase, serine-type carboxypeptidase, tripeptidyl-peptidase, threonine endopeptidase and variants, homologues, derivatives or fragments thereof.

17 . The method of claim 12 , wherein the inflammatory disease is selected from the group consisting of septic shock, septicemia, and adult respiratory disease sybdrome.

18 . The method of claim 12 , wherein the inflammatory disease is an autoimmune disease.

19 . The method of claim 12 , wherein the inflammatory disease is a neurodegenerative disease.

20 . The method of claim 12 , wherein the inflammatory disease is an infectious disease.

21 . A method of modulation of inflammation-related proteins comprising:

modulating the activity of a first protein selected from the group consisting of MMPs and TNFα; and

modulating the activity of a second protein selected from the group consisting of TIMPs and PDGF, wherein the modulation promotes repair of a damaged tissue.

22 . The method of claim 21 , wherein the modulation comprises delivering a protease composition to the damaged tissue.

23 . The method of claim 22 , wherein the protease composition comprises:

at least one protease; and

a pharmaceutically acceptable carrier.

24 . The method of claim 22 , wherein the protease composition is an Elta protease formulation.

25 . The method of claim 21 , wherein the modulation of the activity of the first protein comprises degradation of the first protein.

26 . The method of claim 21 , wherein the modulation of the activity of the second protein comprises protecting the second protein from degradation.

27 . The method of claim 21 , wherein the damaged tissue is a wound.

28 . The method of claim 27 , wherein the wound is an acute wound or a chronic wound.

29 . The method of claim 21 , wherein the damaged tissue is an ulcer.

30 . The method of claim 21 , wherein the damaged tissue is the result of a cancer.

31 . The method of claim 21 , wherein the damaged tissue is the result of an inflammatory disease.

32 . The method of claim 31 , wherein the inflammatory disease is selected from the group consisting of septic shock, septicemia, and adult respiratory disease syndrome, an autoimmune disease, neurodegenerative disease, and an infectious disease.

33 . A method of treating an inflammatory disease in a subject in need thereof comprising:

modulating the activity of a first inflammation-related protein selected from the group consisting of MMPs and TNFα; and

modulating the activity of a second inflammation-related protein selected from the group consisting of TIMPs and PDGF.

34 . The method of claim 33 , wherein the modulation comprises administering to the subject a therapeutically effective amount of a protease composition.

35 . The method of claim 34 , wherein the protease composition comprises:

at least one protease; and

a pharmaceutically acceptable carrier.

36 . The method of claim 33 , wherein the protease composition comprises an Elta protease formulation.